文献速递细菌感染、耐药与抗菌药物

基于IS26的CRISPR/Cas9系统用于大肠杆菌耐药基因清除与免疫

Re-engineering a mobile-CRISPR/Cas9 system for antimicrobial resistance gene curing and immunization in Escherichia coli.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

本研究构建基于IS26的CRISPR/Cas9自杀质粒系统,靶向IncX4、IncI2和IncHI2质粒的复制基因及mcr-1、blaKPC-2、blaNDM-5耐药基因,通过接合与诱导测试转座和质粒清除效率。结果显示三种复制子类型质粒、两个pUC19衍生质粒及携带blaKPC-2和blaNDM-5的质粒均被成功消除,且该系统留在 cured 菌株中可免疫外源耐药质粒的获取。结论提示该系统可在体外有效使临床大肠杆菌分离株对抗生素敏感。

要点

  • IS26-CRISPR/Cas9系统成功清除IncX4、IncI2、IncHI2质粒及mcr-1、blaKPC-2、blaNDM-5耐药基因。
  • 质粒清除后菌株保留该系统,可免疫外源耐药质粒的获取。
  • 该系统为体外使临床大肠杆菌对 antibiotics 敏感提供新方法。

核心结论

  • 基于IS26的CRISPR/Cas9系统可在体外高效使临床大肠杆菌分离株对 antibiotics 敏感。

研究设计与样本

  • 构建一系列pIS26-CRISPR/Cas9自杀质粒,设计特异性guide RNA靶向IncX4、IncI2和IncHI2质粒复制基因及mcr-1、blaKPC-2、blaNDM-5耐药基因。
  • 通过接合和诱导测试各受体菌中的转座效率和质粒清除效率,并将该系统导入抗菌药物敏感宿主以评估对外源耐药质粒获取的免疫效率。

主要发现

  • 成功消除了三种不同复制子类型质粒(IncX4、IncI2、IncHI2)在三株分离株中的存在。
  • 成功消除了两个pUC19衍生质粒pUC19-mcr-1和pUC19-IS26mcr-1在两株实验室菌株中的存在。
  • 成功消除了两株分离株中携带blaKPC-2和blaNDM-5的质粒。
  • 留在质粒清除菌株中的IS26-CRISPR/Cas9系统可有效作为免疫系统对抗外源耐药质粒的获取。

临床怎么用

  • 该系统靶向耐药基因或携带耐药基因的特定不相容群质粒的复制基因,提供了一种自然选择无法摄取和传播这些基因的细菌的新手段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In this study, we developed an IS26-based CRISPR/Cas9 system as a proof-of-concept study to explore the potential of a re-engineered bacterial translocatable unit (TU) for curing and immunizing against the replication genes and antimicrobial resistance genes. METHODS: A series of pIS26-CRISPR/Cas9 suicide plasmids were constructed, and specific guide RNAs were designed to target the replication gene of IncX4, IncI2 and IncHI2 plasmids, and the antibiotic resistance genes mcr-1, blaKPC-2 and blaNDM-5. Through conjugation and induction, the transposition efficiency and plasmid-curing efficiency in each recipient were tested. In addition, we examined the efficiency of the IS26-CRISPR/Cas9 system of cell immunity against the acquisition of the exogenous resistant plasmids by introducing this system into antimicrobial-susceptible hosts. RESULTS: This study aimed to eliminate the replication genes and antimicrobial resistance genes using pIS26-CRISPR/Cas9. Three plasmids with different replicon types, including IncX4, IncI2 and IncHI2 in three isolates, two pUC19-derived plasmids, pUC19-mcr-1 and pUC19-IS26mcr-1, in two lab strains, and two plasmids bearing blaKPC-2 and blaNDM-5 in two isolates were all successfully eliminated. Moreover, the IS26-based CRISPR/Cas9 system that remained in the plasmid-cured strains could efficiently serve as an immune system against the acquisition of the exogenous resistant plasmids. CONCLUSIONS: The IS26-based CRISPR/Cas9 system can be used to efficiently sensitize clinical Escherichia coli isolates to antibiotics in vitro. The single-guide RNAs targeted resistance genes or replication genes of specific incompatible plasmids that harboured resistance genes, providing a novel means to naturally select bacteria that cannot uptake and disseminate such genes.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. He YZ, Kuang X, Long TF, et al. Re-engineering a mobile-CRISPR/Cas9 system for antimicrobial resistance gene curing and immunization in Escherichia coli. J Antimicrob Chemother. 2021. PMID: 34613377. doi:10.1093/jac/dkab368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。